Life-Scienced Bites  

February’s Flux - Facing Fickle Fates with Fortitude and Flexibility!

As February concludes, we dive into the month’s developments in the Life Science industry, both locally and globally. As the gears of the market began their rumblings in January for the new year, February entailed words put into action. This month, we explore the latest developments across four key sectors: Biotechnology, MedTech, Pharmaceuticals, and Healthcare. As always, here’s a life-scienced bite for you dear reader!

Here are the topics for the month!

• Global Instability - Opportunity Disguised?

• Life-Scienced News and Developments

• Star talents

Geopolitical instability - Opportunity Disguised?

As geopolitical uncertainties persist, the APAC region is emerging as a preferred hub for clinical trials, with countries actively improving regulatory efficiency and cost-effectiveness. Singapore, in particular, is strengthening its position as a global leader in MedTech, life sciences innovation, and clinical research.

• Geopolitical Impact: Conflicts in Europe and the Middle East disrupt trial sites, while U.S.-China trade tensions shift API sourcing. Companies are looking for stable trial environments, making APAC an attractive alternative.

• APAC’s Competitive Edge:

  • Singapore: A global MedTech and life sciences innovation hub, with over 400 MedTech companies and 17,000 employees. The MedTech Catapult initiative fosters collaboration between product developers and manufacturers to accelerate innovation.

  • South Korea: Strong patient recruitment in Seoul.

  • Taiwan: Streamlined regulatory processes and cost-effective trials.

  • Australia: R&D tax incentives and rapid trial approvals.

  • Japan: Strengthening global regulatory ties, including a new PMDA office in Washington, DC.

• Future Growth: The global contract research outsourcing market is projected to grow from $49.8 billion in 2022 to $90.4 billion by 2030 (CAGR 7.7%). The Asian MedTech market alone is expected to grow from $164 billion to over $225 billion by 2030.

Singapore’s Role & Market/Employment Insights

• R&D & MedTech Growth: Singapore is a major manufacturer of high-end medical products, producing 10% of the world’s contact lenses and 20% of cardiac implants. The government’s MedTech Catapult initiative aims to strengthen local innovation by connecting contract manufacturers with product developers.

• Investment & Job Creation: The Economic Development Board (EDB) secured S$13.5 billion in Fixed Asset Investments (FAI) in 2024, with healthcare and precision medicine as key focus areas. These investments will create 18,700 jobs over the next five years across manufacturing, R&D, and services.

• Talent Development: Initiatives like A*STAR’s Singapore Biodesign program have trained over 2,000 professionals in MedTech and health innovation, driving a skilled workforce for industry growth.

• Favorable Business Environment: Singapore offers a strong intellectual property regime, facilitating innovation and attracting global companies to establish regional headquarters.

Conclusion

With APAC’s growing role in clinical trials and Singapore’s proactive approach to MedTech and life sciences investment, companies that establish an early foothold in the region will be well-positioned for success. Singapore is not only a stable and innovation-driven hub but also a gateway to Asia’s booming healthcare market.

References:
The APAC Opportunity: Why Clinical Trials Are Shifting East [link]
Post by Ms Jacqueline Soh, Managing Director of EDB [link]
Speech by Mr Tan See Leng, Minister of Manpower Singapore [link]

Life-Scienced News and Developments

As the market gets into gear, it is critical to have an understanding of how things are changing. February marks the period where goals and objectives have been consolidated and market outlooks are shared. Let’s have a look!

• HEALTHCARE

  Higher wages for healthcare workers: In 2025, Singapore will increase salaries for 37,000 public healthcare workers, including allied health professionals, pharmacists, and nurses, to attract and retain talent. The Ministry of Health is also focusing on workforce development, job redesign, and creating a safe work environment to address growing healthcare demands. Read more here.

  Malaysia and Thailand Surge Ahead in Medical Tourism as Singapore Faces Rising Costs: Malaysia and Thailand are attracting more medical tourists than Singapore, offering lower-cost healthcare services. While Singapore remains a key player, rising costs and a strong dollar have made it less competitive, with tourists increasingly turning to Southeast Asia for affordable treatments. Read more here.

• BIOTECHNOLOGY

  Growth in China: China's biotech industry is rapidly growing, supported by regulatory reforms and government incentives. The biopharmaceutical sector is expanding with rising healthcare demand, though local firms lag in R&D. Biomaterials are also gaining traction, with China's market projected to hit $72 billion by 2027. Streamlined approvals and regulatory support make China an attractive biotech hub, despite IP challenges. Read more here.

  Global layoffs in Biotechnology: Market uncertainty, slower growth, and reduced funding have led many companies across industries, including life sciences, to lay off staff. The biotechnology sector, particularly in R&D roles, has been hit hard, with layoffs happening across companies of all sizes. Technological advancements like AI and geopolitical issues in the US and Europe have further added to the challenges. Despite these setbacks, staying strong and continuously adapting to new trends is key to remaining relevant in this evolving landscape. Keep track here.

• PHARMACEUTICALS 

  APAC Pharmaceutical Growth: In 2024, countries in the Asia-Pacific region, including South Korea, China, and Japan, are increasing investments in R&D to strengthen their pharmaceutical sectors. South Korea allocated 5.2% of its GDP to R&D, while China and Japan committed 2.4% and 3.3%, respectively. These investments aim to foster innovation in life sciences, with governments also building advanced research facilities and biotech hubs like China's Zhangjiang Hi-Tech Park to support the growth of the sector. Read more here.

  APAC takes centre-stage in AI-driven drug discovery: The Asia-Pacific region is leading AI-driven drug discovery, with strong research and partnerships. AI's role was validated by AlphaFold’s Nobel win, and it's making drug development faster, safer, and cheaper. Morgan Stanley predicts AI could create 50 successful treatments and a $50 billion market. Read more here.

• MEDTECH

  The rise of MedTech and Biotech in Singapore: Singapore is at the forefront of biotech and MedTech innovation, with advancements in genomic research, cell-based therapies, and AI diagnostics. Government funding through RIE2025 supports growth, while FI Group Singapore helps companies access financial incentives to accelerate development. Read more here.

Star Talents

The Life Science division is always on the lookout to furnish their roster with the experienced and insightful talents. Here, we highlight some of the star talents in our pool who are passively and actively looking for new opportunities.

If you are looking for top-notch individuals to join your team, let us know and we can discuss how we can bring such talents to you!

ACLS1002501 | Marketing Director | Circa $240,000
MedTech | Commercial & Marketing
Singapore | March onwards

ACLS1002502 | Scientific Director/Lead Scientist | Circa $180,000
Food, Nutrition & Microbiology | R&D
Open to relocate | Immediate

ACLS1002503 | Regional Medical Director | Circa $200,000
Oncology & Early Pipeline | Strategy & Innovation
Open to relocate | Immediate

ACLS1002504 | Medical Affairs & Clinical Leader | Circa $250,000
Pharmaceuticals & Medical Devices | Global Strategy & R&D
Open to relocate | Immediate

ACLS1002507 | Head of Marketing | Circa $180,000
Aesthetics & Pharmaceuticals | Marketing Strategy
Open to relocate | Immediate

ACLS1002508 | Regional Commercial Director | Circa $300,000
FMCG & MedTech & Pharmaceuticals | Commercial & Marketing Strategy
Open to relocate | Immediate

ACLS1002511 | Regional Strategic Insights Head | Circa $400,000
Pharmaceuticals | Commercial & Marketing Strategy, Market Insights
Open to relocate | 2 months

ACLS1002512 | R&D Quality Director | Circa $200,000
Pharmaceuticals | Quality, Process Excellence
Open to relocate | Immediate

ACLS1002513 | Regional Head | Circa $250,000
MedTech & Medical Devices | Commercial & Marketing Strategy, Sales
Open to relocate | 2 months

Contact Us: [email protected]
Mobile: +65 9116 7743 Office: +65 6590 9942

Have a free copy of our 2025 Salary Guide, please make a request here.